-
EP3411401
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3411401
| EP3411401 - BUFFER FORMULATIONS FOR ENHANCED ANTIBODY STABILITY [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 01.12.2023 Database last updated on 09.09.2024 | |
| Former | Examination is in progress Status updated on 06.06.2020 | ||
| Former | Request for examination was made Status updated on 09.11.2018 | ||
| Former | The international publication has been made Status updated on 11.08.2017 | ||
| Former | unknown Status updated on 25.02.2017 | Most recent event Tooltip | 01.12.2023 | Application deemed to be withdrawn | published on 03.01.2024 [2024/01] | Applicant(s) | For all designated states Outlook Therapeutics, Inc. 7 Clarke Drive Cranbury, NJ 08512 / US | [2019/30] |
| Former [2018/50] | For all designated states Oncobiologics, Inc. 7 Clarke Drive Cranbury, NJ 08512 / US | Inventor(s) | 01 /
GUTKA, Hiten 7 Clarke Drive Cranbury, New Jersey 08512 / US | 02 /
TADDEI, Maria 7 Clarke Drive Cranbury, New Jersey 08512 / US | 03 /
CHEUNG, Jessica 7 Clarke Drive Cranbury, New Jersey 08512 / US | [2018/50] | Representative(s) | Cooley (UK) LLP 22 Bishopsgate London EC2N 4BQ / GB | [N/P] |
| Former [2018/50] | Cooley (UK) LLP Dashwood 69 Old Broad Street London EC2M 1QS / GB | Application number, filing date | 17705527.4 | 01.02.2017 | [2018/50] | WO2017US16040 | Priority number, date | US201662290654P | 03.02.2016 Original published format: US 201662290654 P | [2018/50] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017136433 | Date: | 10.08.2017 | Language: | EN | [2017/32] | Type: | A1 Application with search report | No.: | EP3411401 | Date: | 12.12.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.08.2017 takes the place of the publication of the European patent application. | [2018/50] | Search report(s) | International search report - published on: | EP | 10.08.2017 | Classification | IPC: | C07K16/24, A61K39/395 | [2018/50] | CPC: |
A61K39/39591 (EP,US);
A61K47/12 (US);
A61K47/183 (US);
A61K47/26 (US);
A61P1/04 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P19/08 (EP);
A61P29/00 (EP);
A61P37/02 (EP);
C07K16/241 (EP,US);
A61K2039/54 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/50] | Title | German: | PUFFERFORMULIERUNGEN FÜR VERSTÄRKTE ANTIKÖRPERSTABILITÄT | [2018/50] | English: | BUFFER FORMULATIONS FOR ENHANCED ANTIBODY STABILITY | [2018/50] | French: | FORMULATIONS DE TAMPON POUR AMÉLIORER LA STABILITÉ D'ANTICORPS | [2018/50] | Entry into regional phase | 07.08.2018 | National basic fee paid | 07.08.2018 | Designation fee(s) paid | 07.08.2018 | Examination fee paid | Examination procedure | 07.08.2018 | Examination requested [2018/50] | 07.08.2018 | Date on which the examining division has become responsible | 18.03.2019 | Amendment by applicant (claims and/or description) | 10.06.2020 | Despatch of a communication from the examining division (Time limit: M06) | 21.12.2020 | Reply to a communication from the examining division | 30.03.2023 | Despatch of a communication from the examining division (Time limit: M04) | 10.08.2023 | Application deemed to be withdrawn, date of legal effect [2024/01] | 31.08.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2024/01] | Fees paid | Renewal fee | 21.02.2019 | Renewal fee patent year 03 | 24.02.2020 | Renewal fee patent year 04 | 22.02.2021 | Renewal fee patent year 05 | 22.02.2022 | Renewal fee patent year 06 | 23.02.2023 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2010278822 (FRAUNHOFER WOLFGANG [US], et al) [A] 1-61 * abstract * * page 22, paragraph 0228 - paragraph 0229 * * page 22; table 16 *; | [I]WO2014039903 (COHERUS BIOSCIENCES INC [US]) [I] 1-61 * abstract * * page 32, line 21 - line 25 * * page 58, line 13 - line 17 * * page 11, line 5 - line 7 * * page 57, line 17 - line 31 * * page 107, line 19 * * page 108, line 2 - line 3 * * page 108, line 4 - line 5 * * page 65; table F *; | [A]EP2946765 (ARES TRADING SA [CH]) [A] 1-61 * abstract * * page 34; table 1 *; | [IP]WO2016066688 (RICHTER GEDEON NYRT [HU]) [IP] 1-61 * page 5, paragraph 4 - page 11, paragraph 1 * * examples 4-9 *; | [IP]WO2016120413 (MABXIENCE S A [UY], et al) [IP] 1-61 * page 16, paragraph 1 - page 17, paragraph 3 *; | [A] - Lindsay Cole, "Screening optimal buffer conditions for a therapeutic antibody using Chirascan(TM)-plus Automated Circular Dichroism", Applied Photophysics, (20120413), pages 1 - 8, URL: http://www.photophysics.com/sites/default/files/documents/application_notes/4210Q244_AppNote_ACD.pdf, (20150630), XP055199259 [A] 1-61 * title * * "introduction" * * page 6, paragraph 5 * | [A] - G. LAPADULA ET AL, "Adalimumab in the Treatment of Immune-Mediated Diseases", INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, GB, (20140101), vol. 27, no. 1_suppl, doi:10.1177/03946320140270S103, ISSN 0394-6320, pages 33 - 48, XP055362182 [A] 1-61 * table; page 36 * DOI: http://dx.doi.org/10.1177/03946320140270S103 | [A] - WANG W ET AL, "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, (20070101), vol. 96, no. 1, doi:10.1002/JPS.20727, ISSN 0022-3549, pages 1 - 26, XP009084505 [A] 1-61 * page 14 - page 15 * * page 15, column r, paragraph 1 * DOI: http://dx.doi.org/10.1002/jps.20727 | by applicant | US6090382 | - KAISER C ??/., RHEUMATOL. INT., (2012), vol. 32, pages 295 - 9 | - FRANSSON J ET AL., J. PHARM. PHARMACOL., (1996), vol. 48, pages 1012 - 5 |